Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer.

Kapil A, Failmezger H, Fu Y, Spitzmüller A, Chan J, Haneder S, Shumilov A, Barkell A, Oguma T, Inaki K, Suto F, Allard J, Lee J, Lambert AW, Schick M, Barrett JC, Schmidt G, Sade H, Gustavson M, Carroll D, Cecchi F

Open source

DOI: 10.1200/po-25-00823
Published: 2026 May
Container: JCO precision oncology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/po-25-00823,
  title = {Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer.},
  author = {Kapil A and Failmezger H and Fu Y and Spitzmüller A and Chan J and Haneder S and Shumilov A and Barkell A and Oguma T and Inaki K and Suto F and Allard J and Lee J and Lambert AW and Schick M and Barrett JC and Schmidt G and Sade H and Gustavson M and Carroll D and Cecchi F},
  year = {2026},
  journal = {JCO precision oncology},
  doi = {10.1200/po-25-00823},
  url = {https://doi.org/10.1200/po-25-00823}
}

RIS

TY  - JOUR
TI  - Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer.
AU  - Kapil A
AU  - Failmezger H
AU  - Fu Y
AU  - Spitzmüller A
AU  - Chan J
AU  - Haneder S
AU  - Shumilov A
AU  - Barkell A
AU  - Oguma T
AU  - Inaki K
AU  - Suto F
AU  - Allard J
AU  - Lee J
AU  - Lambert AW
AU  - Schick M
AU  - Barrett JC
AU  - Schmidt G
AU  - Sade H
AU  - Gustavson M
AU  - Carroll D
AU  - Cecchi F
PY  - 2026
JO  - JCO precision oncology
DO  - 10.1200/po-25-00823
UR  - https://doi.org/10.1200/po-25-00823
ER  -

APA

A, K., H, F., Y, F., A, S., J, C., S, H., A, S., A, B., T, O., K, I., F, S., J, A., J, L., AW, L., M, S., JC, B., G, S., H, S., M, G., D, C., & F, C. (2026). Human Epidermal Growth Factor Receptor 2 Quantification Using Computational Pathology to Identify Novel Biomarkers for Trastuzumab Deruxtecan-Treated Human Epidermal Growth Factor Receptor 2-Positive Gastric Cancer.. JCO precision oncology. https://doi.org/10.1200/po-25-00823

Source records

pubmed · retrieved 2026-09-26T17:12:12.838Z